Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

58.04 -0.10 (-0.17%)
Official Closing Price Updated: 7:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bristol-Myers Squibb

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
31 32 Next >
Bristol Myers Reveals Full Data For Breyanzi In Second-Line Lymphoma Setting
Bristol Myers Squibb & Co (NYSE: BMY) released the first disclosure of results from a prespecified interim analysis of Phase 3 TRANSFORM study of Breyanzi... 
Via Benzinga
The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More
Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound. Multiple... 
Via Benzinga
Exposures Product Safety
5 Dividend Growth Stocks Getting Crushed… Time To Buy?
We have a disconnect between business performance and stock performance. And we have a disconnect between individual stocks and the stock market. These disconnects could lead us to fantastic long-term... 
Via Talk Markets
Infinity Pharma Shares Updated Eganelisib Combo Therapy In Breast Cancer Trial
Infinity Pharmaceuticals Inc (NASDAQ: INFI) presented updated data from the ongoing MARIO-3 study during the 2021 San Antonio Breast Cancer Symposium (SABCS).... 
Via Benzinga
Sunday Memo - Dec. 5
The market rout was worldwide last week. 
Via Talk Markets
Why You Should Buy Moderna Stock at Every Dip
Moderna’s cash growth will continue as demand for booster shots and vaccines for the omicron variant increase, giving a boost to MRNA stock. 
Via InvestorPlace
Exposures COVID-19
Omicron Surge
The seemingly good level of joblessness at a mere 184,000 turns out to be less wonderful than it appears, at the lowest since 1969. 
Via Talk Markets
Where Bristol-Myers Squibb Stands With Analysts
Analysts have provided the following ratings for Bristol-Myers Squibb (NYSE:BMY 
Via Benzinga
How Did Healthcare Stocks Perform Over This Volatile Month?
It’s been a rough month for small-cap biotech stocks amidst a general correction in the market which brought general indices down about 10%. 
Via Talk Markets
A great example of stopping volume on the Bristol-Myers Squibb daily stock chart
We have seen the stock rally from the lows of $53 per share back to $57 per share over the last few days. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021
Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ: 
Via Benzinga
Could Bristol Myers Squibb and Johnson & Johnson Have a Powerful New Blood Thinner on the Way?
It's still early, but so far so good. 
Via The Motley Fool
Charms Of China
Today the global stock market rout was pretty awful. 
Via Talk Markets
Bristol Myers - Merck's Thalassemia Candidate Under FDA Priority Review
The FDA has accepted for review Bristol Myers Squibb Co's (NYSE: BMY) supplemental application seeking approval for Reblozyl (luspatercept-aamt) in adults with... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy Study, Esperion Prices Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Protagonist to Discontinue Development Of Early-Stage Inflammatory Diseases... 
Via Benzinga
AUPH Stock: The Novartis Takeover Talk That Has Aurinia Pharma Shares Taking Off Today
Aurinia Pharma (AUPH) stock is on the rise Thursday as investors hold out hope for a takeover of the company by Novartis (NVS). 
Via InvestorPlace
Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates
A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for... 
Via Benzinga
Exposures Product Safety
7 Drug Stocks to Buy Now While They’re Still on Sale
Covid-19 stocks soared to unsustainable highs as investors ignored drug stocks with a deep pipeline of products for the decade ahead. 
Via InvestorPlace
Topics Supply Chain
Exposures COVID-19 Supply Chain
Mereo BioPharma's Etigilimab/Opdivo Combo Achieves One Complete Response In Cervical Cancer
Mereo BioPharma Group plc (NASDAQ: MREO) reported interim data from ACTIVATE Phase 1b/2 study of its anti-TIGIT antibody, etigilimab, in combination with ... 
Via Benzinga
Better Pharma Stock: GlaxoSmithKline vs. Bristol-Myers Squibb
They're very similar companies on the surface, but one is planning for a big disruption. 
Via The Motley Fool
Jim Cramer Shares His Thoughts On Chegg, Bristol-Myers Squibb And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said with Matterport, Inc. (NASDAQ: 
Via Benzinga
Warren Buffett Is Selling These Stocks
Looking to make money moves like Warren Buffett? Want to know which stocks Buffett is selling? Interested in finding out why these stock sales might be a huge mistake? 
Via Talk Markets
Bristol Myers Squibb Co Drops Again, Here’s The Trade
The next major support level for Bristol Myers Squibb Co stock will be around the $50.00 area. This level is where the stock reversed a big downside decline in March 2020. 
Via Talk Markets
Bristol Myers' Deucravacitinib Under FDA Review For Plaque Psoriasis
The FDA has accepted for review Bristol Myers Squibb & Co's (NYSE: BMY) deucravacitinib for the treatment of adults with moderate to severe plaque psoriasis... 
Via Benzinga
Exposures Product Safety
3 Best Biopharma Stocks to Buy During This Industrywide Fire Sale
Affimed, Amgen, and Bristol Myers Squibb are too cheap to ignore right now. 
Via The Motley Fool
Exposures COVID-19
5 Stocks Insiders Are Selling
When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to... 
Via Benzinga
3 Pharma Stocks That Are Too Cheap to Ignore
Many stocks are ridiculously expensive right now -- but not these three. 
Via The Motley Fool
Bristol Myers' Zeposia Wins European Approval For Ulcerative Colitis
The European Commission has approved Bristol Myers Squibb & Co's (NYSE: BMY) Zeposia (ozanimod) for ulcerative colitis (UC). The approval comes for adult... 
Via Benzinga
The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Synlogic Presents Positive Phase 2 Data For Synthetic Biologic Treatment In... 
Via Benzinga
Exposures COVID-19 Product Safety
AUPH Stock: 13 Things to Know About Aurinia Pharma as Shares Crash Today
Aurinia Pharma (AUPH) stock is taking a beating on Monday following a filing with the SEC after markets closed on Friday. 
Via InvestorPlace
Topics Regulatory Compliance
Exposures Legal Regulatory
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.